- Home
- SOL vs PRLD Comparison
SOL vs PRLD Comparison
Compare SOL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- PRLD
- Stock Information
- Founded
- SOL 2005
- PRLD 2016
- Country
- SOL United States
- PRLD United States
- Employees
- SOL N/A
- PRLD N/A
- Industry
- SOL Semiconductors
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- SOL Technology
- PRLD Health Care
- Exchange
- SOL Nasdaq
- PRLD Nasdaq
- Market Cap
- SOL 84.6M
- PRLD 73.7M
- IPO Year
- SOL 2008
- PRLD 2020
- Fundamental
- Price
- SOL $1.30
- PRLD $0.95
- Analyst Decision
- SOL Buy
- PRLD Strong Buy
- Analyst Count
- SOL 3
- PRLD 2
- Target Price
- SOL $3.50
- PRLD $4.50
- AVG Volume (30 Days)
- SOL 195.2K
- PRLD 157.2K
- Earning Date
- SOL 05-22-2025
- PRLD 05-13-2025
- Dividend Yield
- SOL N/A
- PRLD N/A
- EPS Growth
- SOL N/A
- PRLD N/A
- EPS
- SOL N/A
- PRLD N/A
- Revenue
- SOL $92,067,000.00
- PRLD $7,000,000.00
- Revenue This Year
- SOL N/A
- PRLD N/A
- Revenue Next Year
- SOL $45.37
- PRLD N/A
- P/E Ratio
- SOL N/A
- PRLD N/A
- Revenue Growth
- SOL N/A
- PRLD N/A
- 52 Week Low
- SOL $1.04
- PRLD $0.61
- 52 Week High
- SOL $3.00
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- SOL 44.31
- PRLD 58.11
- Support Level
- SOL $1.25
- PRLD $0.85
- Resistance Level
- SOL $1.40
- PRLD $0.95
- Average True Range (ATR)
- SOL 0.09
- PRLD 0.08
- MACD
- SOL 0.01
- PRLD 0.02
- Stochastic Oscillator
- SOL 46.00
- PRLD 78.46
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.